首页> 外文期刊>Respiration: International Review of Thoracic Diseases >Increased lung uptake of technetium-99m hexamethylpropylene amine oxime in diffuse infiltrative lung disease.
【24h】

Increased lung uptake of technetium-99m hexamethylpropylene amine oxime in diffuse infiltrative lung disease.

机译:在弥漫性浸润性肺病中增加-99m六甲基丙烯胺肟的肺吸收。

获取原文
获取原文并翻译 | 示例
       

摘要

BACKGROUND: Diffuse infiltrative lung disease (ILD) is a heterogeneous group of disorders which predominantly affect the lung parenchyma and spare the airway. OBJECTIVE: To assess pulmonary vascular endothelium damage in ILD, the lung uptake of technetium-99m hexamethylpropylene amine oxime (99mTc-HMPAO) was determined. METHODS: In 20 ILD patients and 25 controls without ILD, the lung uptake of 99mTc-HMPAO was measured. Anterior lung imaging, including a large part of the liver, was made 10 min after intravenous injection of 20-25 mCi of 99mTc-HMPAO. Regions of interest covered the liver and lung to calculate the lung/liver uptake ratios. The 20 ILD patients included 10 patients with clinically manifest pulmonary disease (group 1) and 10 asymptomatic patients (group 2). All of the study subjects had normal pulmonary function test results. RESULTS: The mean lung/liver uptake ratio in the 25 controls without ILD (0.36 +/- 0.10) was significantly lower than that in the 20 ILD patients (0.97 +/- 0.61). In addition, the mean lung/liver uptake ratio in the 10 ILD patients with clinically manifest pulmonary disease (1.45 +/- 0.51) was higher than that of the other 10 asymptomatic ILD patients (0.49 +/- 0.09). CONCLUSIONS: Our results indicated that determining the lung/liver uptake ratio on 99mTc-HMPAO lung imaging should be an objective method to assess subclinical pulmonary damage in ILD patients.
机译:背景:弥漫性浸润性肺病(ILD)是一组异质性疾病,主要影响肺实质并保留气道。目的:为了评估ILD对肺血管内皮的损害,测定了-99m六甲基丙烯胺肟(99mTc-HMPAO)的肺吸收量。方法:在20名ILD患者和25名无ILD的对照组中,测量了99mTc-HMPAO的肺吸收。在静脉内注射20-25 mCi的99mTc-HMPAO 10分钟后,进行了包括肝脏大部分在内的前肺成像。感兴趣的区域覆盖肝和肺,以计算肺/肝摄取率。 20名ILD患者包括10例临床表现为肺部疾病的患者(第1组)和10例无症状的患者(第2组)。所有研究对象的肺功能检查结果均正常。结果:25个无ILD的对照组的平均肺/肝摄取率(0.36 +/- 0.10)显着低于20例ILD患者的(0.97 +/- 0.61)。此外,10例临床表现为肺部疾病的ILD患者的平均肺/肝摄取率(1.45 +/- 0.51)高于其他10例无症状ILD患者的(0.49 +/- 0.09)。结论:我们的结果表明,在99mTc-HMPAO肺部成像中确定肺/肝摄取率应是评估ILD患者亚临床肺损伤的客观方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号